Caris ChromoSeq
A Whole Genome Sequencing (WGS) Assay for Myeloid Malignancies Designed to Bring the Complete Molecular Picture into a Single Test
7 days
Average results turnaround upon specimen receipt
>70 genes
With reported single-nucleotide variants
100%
WGS detected all genomic features identified by karyotyping and FISH1
1 in 4 patients
Had new genetic findings not identified by conventional testing1
50%
Half of patients with newly identified findings were assigned a different risk category1
What it is:
High-coverage WGS that replaces fragmented genetic testing workflows with one actionable, easy-to-interpret report
Why it matters:
Caris ChromoSeq™ results support more confident diagnosis, risk stratification and treatment decisions in myeloid malignancies.
Caris ChromoSeq
Designed for patients with myeloid malignancies
Caris ChromoSeq is indicated:
For Diagnosed or Suspected Cases of Myeloid Malignancy
Diagnosed cases of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), in addition to suspected myeloid malignancies characterized by unexplained cytopenia
At Key Clinical Inflection Point
To confirm the initial diagnosis of myeloid malignancies and support risk stratification and treatment selection
When Speed is Paramount
ChromoSeq’s 7-day average results turnaround is ideal in clinical cases for which time is of the essence
Replaces fragmented genetic testing workflows
such as karyotyping, FISH and targeted NGS panels with a single assay
Uses high-coverage WGS
Mapped read depth of ~200x to detect structural variants, copy number alterations and mutations genome-wide
Synthesizes multiple test results
into one actionable, easy-to-interpret report
7-day average turnaround
upon receipt of sample specimen
TESTING WORKFLOW
How Caris ChromoSeq Works
Sample is Collected
A 2 mL bone marrow aspirate or peripheral whole blood sample is collected and shipped to our lab in a proprietary collection tube within the ChromoSeq kit.
Whole Genome Sequencing (WGS) is Performed
Using WGS, Caris ChromoSeq analyzes the entire genome in a single assay.
Average 7-Day Turnaround Time
Advanced bioinformatics and expert review translate complex genomic data into clinically meaningful insights.
Receive One Molecular Profiling Report
Receive a single, comprehensive report designed to reduce complexity and support confident clinical decision making.
Test results
Easy-to-Interpret Report to Support Clinical Decisions
One integrated test with one report that provides clearer diagnostic insight.
AFFORDABILITY
Financial Flexibility for Patients
At Caris, we believe cancer diagnostic testing should be accessible to everyone. Our team is ready to support you with any insurance or billing questions.
Many patients don’t realize
- If you are uninsured or worried about cost, we offer financial assistance programs to help eligible patients get the testing they need without added stress.
- Caris ChromoSeq is a covered benefit for Medicare beneficiaries, including Medicare and Medicare Advantage Plans. Qualifying Medicare/Medicaid patients have no out-of-pocket responsibility.
- Most patients will be responsible for less than $100 USD out-of-pocket, including co-pays, co-insurance and deductibles. If your invoice is $100 USD or more, Caris will call you to discuss financial assistance options.
Specimen Requirements
Sample and Laboratory Specifications
Specimen Type
Bone marrow aspirate or whole blood
Minimum Input
2ML
Variant Coverage
- Single nucleotide variants
- Gene mutations
- Structural variants
- Copy number alterations
Document Downloads
Email the completed form(s) to CustomerSupport@CarisLS.com, or fax to 1.866.479.4925. When specimen is being prepared for shipment, please include completed forms with the shipper. Not available in all locations.
1. Duncavage EJ, et al. (2021) N Engl J Med 384, 924-935.
Next Steps
Caris ChromoSeq